PDCD1 and non-small cell lung carcinoma: Rizvi et al firstly determined the mutational landscape of NSCLC patients treated with PD-1 blockades, and found that high-TMB patients had significantly improved response rate and progression-free survival (PFS) than low-TMB patients [16].